Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events
about
Proteome Analysis of Renoprotection Mediated by a Novel Cyclic Helix B Peptide in Acute Kidney Injury.LIGAND-RECEPTOR INTERACTIONS AND DRUG DESIGN.Cytoprotective effect of glutaraldehyde erythropoietin on HEK293 kidney cells after silver nanoparticle exposure.Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.Erythropoietin and co.: intrinsic structure and functional disorder.Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension.Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.EPOR2/βcR2-independendent effects of low-dose epoetin-α in porcine liver transplantation.Erythropoietin Attenuates Postoperative Cognitive Dysfunction by Shifting Macrophage Activation toward the M2 Phenotype.Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings.Erythropoiesis stimulating agents and nephroprotection: is there any room for new trials?
P2860
Q36361390-7201DC93-FF7E-42EC-9422-96143EF6D4FDQ36395316-317D1F67-6F0A-4A4C-B0C5-CF92C3837248Q36597314-02EC458A-EE98-4765-B972-3EFF19CD5EB1Q37097716-7E3DCCC1-A1B7-4630-807D-81317D0AAF0FQ38740871-B2CF96C6-150C-44A7-88C5-44FD9594D3AFQ39005050-07CBAAA3-4AC3-4954-B010-6C498B330E25Q39266683-453F247C-EC83-4E20-B5C9-0FC1B282D02DQ41229491-77BFCA8D-CA22-4CC2-B51A-770167300271Q47093489-A3044F02-E5E6-49EC-96E2-3306B4235BFCQ47141414-EEBA7499-A4B7-4AF6-883B-0F9C7503827AQ47634204-B611FE9E-3CAD-4F8D-B973-E3251D2B08EEQ53513618-9D99D9C3-3FDA-47C6-83FA-21469AD9DF61
P2860
Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Erythropoietin-mediated protec ...... risk of cardiovascular events
@ast
Erythropoietin-mediated protec ...... risk of cardiovascular events
@en
Erythropoietin-mediated protec ...... risk of cardiovascular events
@nl
type
label
Erythropoietin-mediated protec ...... risk of cardiovascular events
@ast
Erythropoietin-mediated protec ...... risk of cardiovascular events
@en
Erythropoietin-mediated protec ...... risk of cardiovascular events
@nl
prefLabel
Erythropoietin-mediated protec ...... risk of cardiovascular events
@ast
Erythropoietin-mediated protec ...... risk of cardiovascular events
@en
Erythropoietin-mediated protec ...... risk of cardiovascular events
@nl
P2093
P2860
P356
P1476
Erythropoietin-mediated protec ...... risk of cardiovascular events
@en
P2093
Henri G. D. Leuvenink
Rutger J. Ploeg
Willem G. van Rijt
P2860
P356
10.1111/TRI.12174
P407
P577
2014-03-01T00:00:00Z